Welcome to our dedicated page for Applied Molecular Transport news (Ticker: AMTI), a resource for investors and traders seeking the latest updates and insights on Applied Molecular Transport stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Applied Molecular Transport's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Applied Molecular Transport's position in the market.
Applied Molecular Transport Inc. (Nasdaq: AMTI) announced that CEO and co-founder, Tahir Mahmood, Ph.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 3:30 p.m. ET. This event will be accessible via a live webcast on their website, with an archived replay available for 30 days afterward.
Applied Molecular Transport is a clinical-stage biopharmaceutical company focused on developing novel oral biologic therapies for autoimmune and inflammatory diseases using its proprietary technology platform.
Applied Molecular Transport Inc. (AMTI) reported third quarter 2020 results, highlighting the advancement of its AMT-101 Phase 2 clinical program targeting inflammatory bowel diseases and rheumatoid arthritis. The company initiated the LOMBARD trial for oral AMT-101 in ulcerative colitis, with more trials planned by year-end. R&D expenses increased to $13.4 million, and G&A expenses rose to $3.4 million, leading to a net loss of $16.8 million. As of September 30, 2020, cash and investments stood at $147.3 million.
Applied Molecular Transport (Nasdaq: AMTI) announced that CEO Tahir Mahmood, Ph.D., and CMO Bittoo Kanwar, M.D., will engage in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 12:00 p.m. ET / 5:00 p.m. GMT. A live webcast can be accessed through the company’s Events page, with an archived replay available for 30 days after the event.
AMT is focused on developing novel oral biologic therapies for autoimmune, inflammatory, and metabolic diseases, utilizing a unique technology platform for effective intestinal transport.
Applied Molecular Transport (AMTI) announced promising preclinical results for AMT-101, a novel oral biologic targeting ulcerative colitis (UC). The data, published in The Journal of Immunology, highlights AMT-101's efficiency in transporting through intestinal epithelia with minimal systemic exposure. The therapy demonstrates an ability to suppress inflammatory markers while inducing an anti-inflammatory response in colitis models. AMTI also revealed positive outcomes from a Phase 1b study, showing reductions in clinical signs of inflammation in UC patients after just 14 days of treatment.
Applied Molecular Transport (Nasdaq: AMTI) announced today that its CEO, Tahir Mahmood, and CMO, Bittoo Kanwar, will participate in a fireside chat at the Jefferies Next Generation IBD Therapeutics Virtual Summit. This event is scheduled for September 23, 2020, at 8:00 a.m. ET and will be available via a webcast on the company’s website. An archived replay will be accessible for 30 days after the event. AMT focuses on developing novel oral biologic therapies for autoimmune and inflammatory diseases, utilizing its proprietary technology platform.
Applied Molecular Transport (Nasdaq: AMTI) announced the initiation of a Phase 2a clinical trial for AMT-101, an oral biologic aimed at treating moderate to severely active ulcerative colitis (UC). The trial, which will involve around 100 adult patients across 20 countries, is designed to assess the efficacy and safety of AMT-101 versus placebo over 12 weeks. AMT-101 uniquely targets the gastrointestinal tract, potentially minimizing systemic side effects. The company is optimistic about AMT-101's broader therapeutic applications, planning additional Phase 2 studies for other indications.
Applied Molecular Transport (NASDAQ: AMTI) successfully debuted with a $177 million IPO, enhancing its financial position significantly. The company plans multiple Phase 2 clinical trials for its lead candidate AMT-101, with pivotal data expected in 2021 and 2022. Recent Phase 1a/b results for AMT-101 revealed positive trends in ulcerative colitis patients, and the drug was well tolerated. Q2 2020 saw a net loss of $15.4 million, up from $7.3 million in 2019, while cash on hand increased to $163.3 million, driven by the IPO.
Applied Molecular Transport (Nasdaq: AMTI) announced the successful closing of its initial public offering (IPO) on June 9, 2020, offering 12,650,000 shares at $14.00 per share, generating gross proceeds of $177.1 million. The offering included the full exercise of underwriters' options for an additional 1,650,000 shares. AMTI's stock began trading on June 5, 2020. The company focuses on developing oral biologic therapies using its proprietary technology platform.
Applied Molecular Transport (Nasdaq: AMTI) announced the pricing of its initial public offering (IPO) of 11,000,000 shares at $14.00 per share, expecting gross proceeds of $154 million. Trading is set to begin on NASDAQ on June 5, 2020, with the IPO closing on June 9, 2020, pending usual conditions. The offering includes a 30-day option for underwriters to buy an additional 1,650,000 shares. BofA Securities, Jefferies, and SVB Leerink are the managing underwriters.